Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2003-06-13
2008-05-27
Oh, Taylor Victor (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S560000, C514S625000, C554S061000, C554S219000
Reexamination Certificate
active
07378444
ABSTRACT:
The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 ω-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.
REFERENCES:
patent: 5411951 (1995-05-01), Mitchell
patent: 5441951 (1995-08-01), Serhan
patent: 2002/0055538 (2002-05-01), Serhan et al.
patent: 2003/0191184 (2003-10-01), Serhan et al.
patent: 2003/0236423 (2003-12-01), Petasis
patent: 2004/0019110 (2004-01-01), Van Dyke et al.
patent: WO 00/55109 (2000-09-01), None
patent: WO 01/60778 (2001-08-01), None
patent: WO 01/70664 (2001-09-01), None
patent: WO 03/053423 (2003-07-01), None
patent: WO 03/084305 (2003-10-01), None
Serhan et al, Novel functional sets of lipid-derived mediators, Oct. 2000, Rockfeller University press, 192(8), p. 1197-1204.
Iigo et al. (1997), “Inhibitory Effects of Docosahexaenoic Acid on Colon Carcinoma 26 Metastasis to the Lung”,Br. J. Cancer, 75:650.
Billman et al., “Prevention of Sudden Cardiac Death by Dietary Pure Omega-3 Polyunsaturated Fatty Acids in Dogs” (1999),Circulation, 99:2452.
Simopoulous, et al, “Workshop on the Essentiality of and Recommended Dietary Intakes for Omega-6 and Omega-3 Fatty Acids”(1999),J. Am. Coll. Nutr., 18:487.
Marchioloi et al. “Dietary Supplementation with n-3 Polyunsaturated Fatty Acids and Vitamin E After Myocardial Infarction: Results of the GISSI-Prevenzione Trial” (1999),Lancet, 354:447.
Weissmann, G. “Aspirin” (1991),Sci, Am., 264:84.
Marcus, A.J. (1999), “Platelets: Their Roll in Hemostasis, Thrombosis, and Inflammation”Inflammation: Basic Principles and Clinical Correlates, J.I. Gallin and R. Snyderman, Editors, Lippincott Williams & Wilkins, Philadelphia, pp. 77-79.
Clária, J. et al. “Aspirin Triggers Previously Undescribed Bioactive Eicosanoids by Human Endothelial Cell-Leukocyte Interactions” (1995),Proc. Natl. Acad. SciUSA, 92:9475.
Serhan et al. “Design of Lipoxin A4Stable Analogs That Block Transmigration and Adhesion of Human Neutrophils” (1995),Biochemistry, 34:14609.
Chiang et al. “Leukotriene B4Receptor Transgenic Mice Reveal Novel Protective Roles for Lipoxins and Aspirin-Triggered Lipoxins in Reperfusion” (1999),J. Clin. Invest. 104:309.
Chiang et al. “Aspirin-Triggered 15-epi-Lipoxin A4(ATL) Generation by Human Leukocytes and Murione Peritonitis Exudates: Development of a Specific 15-epi-LXA4ELISA1” (1998), J. Pharmacol. Exp. Ther., 287:779.
Xiao et al. “Analysis of Hydroperoxide-Induced Tyrosyl Radicals and Lipoxygenase Activity in Aspirin-Treated Human Prostaglandin H Synthase-2” (1997), Biochemistry, 36:1836.
Clish et al. “Local and Systemic Delivery of a Stable Aspirin-Triggered Lipoxin Prevents Neutrophil Recruitment in vivo” (1999),Proc. Natl. Acad. SciUSA, 96:8247.
Serhan et al. “Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2-Nonsteroidal Antiinflammatory Drugs and Transcellular Processing” (2000),J. Exp. Med., 192:1197.
Cronstein et al. “A Mechanism For the Antiinflammatory Effects of Corticosteroids: The Glucocorticoid Receptor Regulates Leukocyte Adhesion to Endothelial Cells and Expression of Endothelial-Leukocyte Adhesion Molecule 1 and Intercellular Adhesion Molecule 1” (1992),Proc. Natl. Acad. SciUSA, 89:9991.
Webber et al. The Total Synthesis of the Lipoxins and Related Compounds (1988),Adv. Exp. Med. Biol., 229:61.
Radüchel, B., et al. “Prostagladin Analogs” (1985),Adv. Prost. Thromb. Leuko. Res., 14:263.
Kobayashi, Y. et al “Highly Stereocontrolled Total Synthesis of Leukotriene B420-Hydroxyleukotriene B4Leukotriene B3and Their Analogues” (1990),J. Org. Chem., 55:5324.
Nicolaou, K.C. et al. “Lipoxins and Related Eicosanoids: Biosynthesis, Biological Properties, and Chemical Synthesis” (1991),Agnew Chem. Int. Ed. Engl., 30:1100.
Serhan, C. et al. “High-Performance Liquid Chromatography Separation and Determination of Lipoxins” (1990),Meth. Enzymol., 187:167.
Minto, C.F. et al., “Pharmacokinetics and Pharmacodynamics of Nandrolone Esters in Oil Vehicle: Effects of Ester, Injection Site and Injection Volume1” (1997),J. Pharmacol. Exp. Ther., 281:93.
Rohatagi et al. “Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration” (1995),J. Clin. Pharmacol., 35:1187.
Tjwa, Martin K.T. “Budesonide Inhaled via Turbuhaler: A More Effective Treatement for Asthma Than Beclomethasone Dipropionate Via Rotahaler” (1995),Ann. Allergy Asthma&Immunol., 75:107.
Rao, K.P. “Recent Developments of Collagen-Based Mterials for Medical Applications and Drug Delivery Systems” (1995),J. Biomater Sci. Polym. Edn, 7:623.
Gao, Z. et al. “Controlled Release of a Contraceptive Steroid from Biodegradable and Injectable Gel Formulations: In Vitro Evaluation” (1995),Pharm. Res., 12:857.
Eyles et al. “Oral Delivery and Fate of Poly(lactic Acid) Microsphere-Encapsulated Interferon in Rats” (1997),J. Pharm. Pharmacol., 49:669.
Al-Muhammed et al. “In-Vivo Studies on Dexamethasone Sodium Phosphate Liposomes” (1996),J. Microencapsul., 13:293.
Ostro, M.J. et al. “Use of Liposomes as Injectable-Drug Delivery Systems” (1989),Am. J. Hosp. Pharm., 46:1576.
Shimazaki et al., “12 (R)-Methyl-Leukotriene B3: A Stable Leukotriene B Analogue Toward the Reductase Metabolism” (1993),Prostaglandins, 45:335.
Kobayashi et al., “Highly Stereocontrolled, Multigram Scale Synthesis of Leukotriene B4” (1987),Tetrahedron Lett., 38:5849.
Clissold D. “The Potential For Prostaglandin Pharmaceuticals” (1999), Lipids in Health and Nutrition, J.H.P. Tyman editor, Royal Society of Chemistry, Cambridge UK, pp. 115-129.
Serhan et al., “Unorthodox Routes to Prostanoid Formation: New Twists in Cyclooxygenase-Initiated Pathways” (2001),J. Clin. Invest., 107:1481.
Serhan et al., “Resolvins: A Family of Bioactive Products of Omega-3 Fatty Acid Transformation Circuits Initiated by Aspirin Treatment that Counter Proinflammation Signals” (2002),J. Exp. Med., 196:1025.
Serhan et al., “Lipid-Derived Mediators in Endogenous Anit-Inflammation and Resolution: Lipoxins and Asiprin-Triggered 15-epi-Lipoxins” (2002),TheScientificWorldJOURNAL, 2:169.
Clish et al., “Oxidoreductases In Lipoxin A4Metabolic Inactivation” (2000),J. Bio Chem., 275:25372.
Takano et al., “Aspirin-Triggered 15-Epi-Lipoxin A4(LXA4) and LXA4Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Anti-Inflammatory Receptors” (1997),J. Exp. Med., 185:1693.
Konno et al., “Synthesis of Structural Analogues of Leukotriene B4and their Receptor Binding Activity” (1997),Biorg. &Med. Chem., 4:1621.
Serhan et al., “Anit-Microinflammatory Lipid Signals Generated from Dietary N-3 Fatty Acids Via Cyclooxygenase-2 and Transcellular Processing: A Novel Mechanism for Nsaid and N-3 PUFA Therapeutic Actions” (2000),J. Physiol. Pharmacol. 51:643:54.
Bursten Stuart L.
Goodman Daniel W.
Hanley Michael R.
Serhan Charles N.
Brigham and Women's Hospital, Inc.
Oh Taylor Victor
Resolvyx Pharmaceuticals, Inc.
LandOfFree
Analogues of lipid mediators derived from omega-3 PUFAs and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Analogues of lipid mediators derived from omega-3 PUFAs and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analogues of lipid mediators derived from omega-3 PUFAs and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3983154